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Purpose: To evaluate the value of dynamic contrast enhanced Magnetic Resonance Imaging (DCE-MRI) without
endorectal coil (EC) in the detection of local recurrent prostate cancer (PC) after radical prostatectomy (RP).
Material and methods: Thirty-three patients with recurrent PC underwent DCE-MRI without EC before salvage
radiotherapy (RT). At median 15 (mean 16±4.9, range 12–27) months after completion of RT all patients showed
complete biochemical response. Additional follow up post RT DCE-MRI scans were available. Prostate specific
antigen (PSA) levels at the time of imaging were correlated to the imaging findings.
Results: In 22/33 patients (67%) early contrast enhancing nodules were detected in the post-prostatectomy fossa
on pre-RT DCE-MRI images. The average pre-RT PSA level of the 22 patients with positive pre-RT DCE-MRI findings
was significantly higher (mean, 0.74±0.64 ng/mL) compared to the pre-RT PSA level of the 11 patients with
negative pre-RT DCE-MRI (mean, 0.24±0.13 ng/mL) (p<0.001). All post-RT DCE-MRI images showed complete
resolution of initial suspicious lesions. A pre-RT PSA cut-off value of ≥0.54 ng/ml readily predicted a positive
DCE-MRI finding.
Conclusions: This is the first study that shows that DCE-MRI without EC can detect local recurrent PC with an
estimated accuracy of 83% at low PSA levels. All false negative DCE-MRI scans were detected using a PSA cut-off of
≥0.54 ng/mL.
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Salvage radiotherapy (RT) of the prostate fossa is consid-
ered the standard therapeutic intervention that offers a
potential of cure for patients with post-radical prostatec-
tomy (RP) local recurrence [1]. Serum prostate specific
antigen (PSA) kinetic is the most accurate and early
index for detecting prostate cancer (PC) recurrence after
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reproduction in any medium, provided the orGleason-score and resection status, 10 to 53% of patients
develop a biochemical relapse following RP [4].
Local PC recurrence can most accurately be detected
on Magnetic Resonance Imaging (MRI) [5,6]. The sensi-
tivity and specificity of this imaging test was further
improved by the introduction of dynamic contrast
enhanced (DCE)-MRI with endorectal coil (EC) [7,8].
DCE-MRI visualizes tumor neo-vascularisation, which is
typically found in PC, showing rapid enhancement in
the first 90 seconds after intravenous administration of
gadolinium contrast agent [9-11].
Dose escalation in salvage radiation therapy has been
shown to improve PSA relapse free rates [12-14].Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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fossa, the target volume in clinical practice, increases the
risk of acute and chronic side effects to adjacent organs
at risk, predominantly rectal wall, bladder, and bowel
loops located in the pelvis [15].
A recently published regression meta-analysis of
twenty five published reports about the outcome of sal-
vage RT comprised a total of 3828 patients [16]. In this
study Ohri et al. identified increased salvage RT dose
and decreased pre-salvage RT PSA level as independent
predictors of improved 5-year biochemical free survival.
Salvage RT dose was also identified as an independent
predictor of both late gastrointestinal and late genitour-
inary toxicity. They generated tumor control probabil-
ities (TCP) and normal tissue complication probabilities
(NTCP) models that can be used to predict rates of dis-
ease control and severe late toxicity. For example with a
pre-salvage RT PSA-level of 0.4 ng/mL an approximately
50% chance of 5-year biochemical free survival can be
achieved with a salvage RT dose of 60 Gy. Severe late
toxicity rates with this dose are on the order of 1%. If
the PSA level before salvage RT is 1.0 ng/mL, than dose
of approximately 70 Gy may be required to achieve the
same probability of disease control, but severe late tox-
icity rates at that dose level may reach 10%, if those
patients will be treated with conventional RT-technique.
The model by Ohri et al. demonstrated that the gain
from dose escalation is greater when PSA is high (that
means PSA of 1.5 ng/mL).
MRI with endorectal coil is superior over computer
tomography (CT) in detecting local recurrent PC. How-
ever, MRI with endorectal coil causes a distortion of
local anatomy and therefore does not allow image fusion
with RT-planning CT to define a gross tumor volume
(GTV) for targeted dose escalation.
An Imaging modality to identify and correctly localize
local PC recurrence without induced distortion of the
local anatomy in the small pelvis is therefore strongly
desirable and may offer the opportunity to reduce acute
and late toxicities.
Therefore, the aims of this retrospective study were
threefold. First, we determined the accuracy of DCE-
MRI without endorectal coil in the detection of local re-
current PC at low PSA levels. Secondly, we assessed the
predictability of a false negative DCE-MRI without EC.




The database of the University Hospital of Freiburg was
retrospectively analysed for post-RP patients that were
treated by salvage RT of the whole fossa prostatica for
local recurrent PC between January 2007 and January2010. Of these patients, only those who showed
complete biochemical response ≥ 12 months after com-
pletion of salvage RT, defined by a PSA below detection
level, and those who underwent a DCE-MRI without EC
of the pelvis before the initiation of salvage RT were
included in this study. Additionally metastatic disease
was ruled out using Choline-PET or Choline-PET/CT
imaging in all patients. Patients who underwent anti-
androgen therapy before or after salvage RT were
excluded from this analysis. Follow up DCE-MRI with-
out EC had to be performed ≥ 12 months after comple-
tion of salvage RT and was used as internal reference to
specify whether contrast enhancing tumor lesions in the
prostate fossa show complete response in accordance to
complete biochemical response.
For this retrospective study, the University of Freiburg Insti-
tutional Review Board waived the consent requirements.
DCE-MRI technique
DCE-MRI scans were acquired on 1.5-Tesla systems
(Magnetom Avanto, Espree or Symphony, Siemens Med-
ical Solutions, Erlangen, Germany), each equipped with
surface phased array (Body Matrix, Siemens Medical
Solutions). MRI acquisition parameters differed between
scanners. Imaging of the post-prostatectomy fossa was
performed by acquiring turbo spin echo (TSE) T2-
weighted sequences in the axial, sagittal and coronal
planes (repetition time [TR], 9200–9500 ms; echo time
[TE], 119–128 ms; flip angle 150–160; field of view 150–
300 mm; thickness 3 mm; section gap 0; matrix, 192 x
192 to 512 x 512).
An axial turbo spin echo (TSE) T1-weighted series of
the whole pelvis was then obtained with the following
parameters: repetition time [TR], 798 ms; echo time
[TE], 9,8 ms; flip angle 150; field of view 380 mm; thick-
ness 3 mm; section gap 0; matrix, 384 x 288. The last
series performed was a 3D, fast low-angle shot (FLASH),
T1-weighted spoiled gradient-echo sequence in axial
plane (TR, 4.3 – 5.41 ms; TE, 1.82-2.39 ms; flip angle
10–15, field of view 380 mm, thickness 2 mm; section
gap 0; matrix, 384 x 264 – 384 x 288) to perform 4–10
measurements in rapid succession, immediately follow-
ing completion of an intravenous bolus injection of 0.15
ml/kg gadopentetate dimeglumine (Multihance, Bracco)
using a power injector (Medtron) at 2 ml/s followed by a
30 ml saline flush. Therefore time resolution varied be-
tween 20 and 40 seconds.
Image analysis
A board certified radiologist with 8 years of experience
in urogenital MRI imaging (HCR) who was blinded to
clinical and biochemical information analysed all pre-
and post-RT DCE-MRI scans. The lesion location was
recorded and the perpendicular diameter was calculated
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diameters.
Pre- and post-RT DCE-MRI images of the prostatic
bed were analysed according to following classifications:
True positive DCE-MRI: Suspicious early contrast
enhancing lesion (visual determined peak enhancement
within 90 seconds post injection) in the post-
prostatectomy fossa on pre-RT DCE-MRI scan and
elevated PSA level (≥0.08 ng/mL).
False positive DCE-MRI: Suspicious early contrast
enhancing lesion (visual peak enhancement within 90
seconds post injection) in the post-prostatectomy fossa
on pre-RT DCE-MRI scan and elevated PSA level
(≥0.08 ng/mL), that shows no significant morphologic
changes on post-RT DCE-MRI while PSA remission is
detected.
False negative DCE-MRI: Elevated PSA level
(≥0.08 ng/mL) but absence of a suspicious contrast
enhancing lesion in the post-prostatectomy fossa on
pre RT DCE MRI scan.
True negative DCE-MRI: Absence of a suspicious
contrast enhancing lesion in the post-prostatectomy
fossa on DCE-MRI scan, and PSA below detection
level. Because all 33 patients showed a complete
biochemical response, all post RT-DCE-MRI scans
were used as an internal negative control in this
setting. This is based on the fact that radiotherapy is a
highly effective treatment and on the consideration that
RT has the potential to entirely degrade tumor nodules
including their neo-vascularization leading to non-
enhancing post-RT-fibrosis similar to non-enhancing
post-surgical fibrosis in the post prostatectomy fossa
[8,17].Treatment characteristics
All patients received salvage RT of the whole fossa pros-
tatica with 63.0 to 70.2 Gy (mean 68.1, median 68.2 Gy),
5 × 1.8 Gy/week. Dose escalation to 70.2 Gy was per-
formed, when both diagnostic methods, DCE-MRI as
well as Choline-PET detected a finding suspicious of
local recurrence in the fossa prostatica.Statistical analysis
Quantitative data are presented as median, mean ± SD
and range. The Mann–Whitney test was used for unpaired
comparisons between quantitative parameters. The Spear-
man rank test was used for correlations between PSA
levels and tumor volume/diameters. P values <0.05 were
considered statistically significant. Statistical analyses were
performed using SPSS© software for Windows© (version
14.0, SPSS Inc., Chicago, USA) and JMP© software for
Windows© (release 5.0.1.2).Results
Patient characteristics
Between January 2007 and January 2010, 54 patients
underwent post-RP salvage RT for local recurrent pros-
tate cancer in our institution. Thirty-three of the 54 con-
secutive patients (61%) met the above listed inclusion/
exclusion criteria.
The time interval between RP and PSA recurrence
averaged 46±41.6 months (median, 35 months: range,
4–204 months). Salvage RT was initiated 2.7±2.2 weeks
(median, 2 weeks; range, 1–12 weeks) after the pre-RT
DCE-MRI. The post-RT DCE-MRI was performed at
median 15 months (mean 16±4.9, range, 12–27 months)
following RT.
PSA levels
The PSA level averaged 0.57±0.58 ng/ml (median, 0.34 ng/
mL; range, 0.08-2.38 ng/mL) at the time of local re-
currence. All patients exhibited a complete biochemical
response following RT, PSA was then below detection level
(detection cut off level varied between different laboratory
tests, mean, 0.02±0.03 ng/mL; median, 0.00 ng/mL;
range 0.00 - 0.07 ng/mL) (Table 1).
DCE-MRI findings
In 22 of the 33 patients (67%) a total of 24 suspicious
early contrast enhancing nodules were detected, located
in the post-prostatectomy fossa on pre-RT DCE-MRI
images. The lesion’s characteristics are summarized in
Table 2. Lesions exhibited a complete morphologic re-
sponse along with a complete biochemical response
post-RT, and were therefore classified as true positive.
All but two lesions were located between the 1 and 10
o’clock position in relation to the vesicourethral anasto-
mosis, most frequently around the posterior and lateral
aspects. One lesion was located between the 10 and 12
o’clock, and another one between the 11 and 1 o’clock
position, respectively.
The maximum pre-RT tumor diameter in the 24 lesions
averaged 1.1±0.4 cm (median, 1.0 cm; range, 0.5 – 2.0 cm).
The average tumor volume measured 0.4±0.4 mL (median
0.2 mL; range, 0.1 – 1.5 mL) (Table 2).
Figure 1a and b show a pre-RT and post-RT DCE-MRI
without EC of a patient classified as true positive.
Eleven of the 33 patients (33%) did not exhibit a suspi-
cious lesion on the pre-RT DCE-MRI scans, but elevated
pre-RT PSA levels (mean 0.24±0.13 ng/mL; median, 0.22
ng/mL; range, 0.08 - 0.53 ng/mL), with post-RT showing
decrease below detection levels (complete PSA remission).
Therefore, 11 patients were classified as false negative.
All post-RT DCE-MRI showed absence of suspicious
contrast enhancing lesions together with complete PSA
remission post-RT. Therefore, the post-RT DCE-MRI
findings were used as a negative control to calculate the
Table 1 Patient characteristics (n=33)
Characteristics
Age (years) at PSA recurrence


























Table 2 Characteristics of lesions classified as true
positive
Characteristics n (%)
Number of suspicious lesions per patient
unifocal 20 (91)
bifocal 2 (9)
















*Two patients had bifocal lesions, one of them in two different locations
therefore the numbers add up to 24.
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dictive value (NPV), and the accuracy of DCE-MRI with-
out EC. The sensitivity and specificity of DCE-MRI
without endorectal coil in detecting local recurrent PC
was 67% and 100%, respectively. The PPV, NPV, and the
accuracy was 100%, 75% and 83%, respectively.
Correlation between tumor volume/size and PSA level
The pre-RT tumor diameters and tumor volumes of the
22 patients with positive pre-RT DCE-MRI findings were
significantly correlated to pre-RT PSA levels (Spearman
rank correlation coefficient for correlation between tumor
volume and PSA level = 0.83, p<0.001 (Figure 2a); Spear-
man rank correlation coefficient for correlation between
tumor diameter and PSA level = 0.47, p=0.03 (Figure 2b)).
Predictability of a positive DCE-MRI finding
The average pre-RT PSA levels of the 22 patients with
positive pre-RT DCE-MRI findings were significantlyhigher (mean, 0.74±0.64 ng/mL; median, 0.51 ng/mL,
range, 0.11-2.38) compared to the pre-RT PSA levels of
the 11 patients with negative pre-RT DCE-MRI (mean,
0.24±0.13 ng/mL; median, 0.22 ng/mL, range, 0.08-0.53)
(p<0.001) (Figure 3). A pre-RT PSA cut-off value of
≥0.54 ng/ml readily predicted a positive DCE-MRI find-
ing (Figure 3).Characterization of a common DCE-MRI pattern
We observed in 27 of the 33 patients (82%) an un-
equivocal contrast enhancement in the diaphragma uro-
genitale at the anterior aspect of the proximal urethra
immediately below the vesicourethral anastomosis, with
no obvious change on post-RT DCE-MRI demonstrating
no obvious change following RT (Figure 4a and b). In 6
of the 33 patients (18%) no enhancement of the prox-
imal urethra was evident. The periurethral enhancement
was located at midline with a lobulated or circular aspect
of symmetrical shape. The diameter averaged 1.0±0.3 cm
(median, 1.0 cm; range, 0.5 – 1.9 cm).Discussion
To the best of our knowledge this is the first study that
describes the detectability of recurrent PC using DCE-
MRI without EC in the setting of very low PSA-levels.
Figure 1 Example of a patient classified as true positive. A contrast enhancing lesion was detected on pre-RT DCE-MRI (a) (arrowhead), with
completely morphologic response on the post-RT DCE-MRI (b).
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accuracy of 83%. The pre-RT tumor volumes of the 22
patients with positive pre-RT DCE-MRI findings showed
high correlation to pre-RT PSA levels. Our results also
indicate a correlation between lesion detectability and
increasing PSA-level. A PSA cut-off of ≥0.54 ng/mL
detected all lesions positive on DCE-MRI as true posi-
tive. We also alert radiation oncologists to acknowledge
a commonly observed unequivocal contrast enhance-
ment at the anterior aspect of the proximal urethra im-
mediately below the vesicourethral anastomosis, which
represents physiological contrast enhancement.
Modern three-dimensional RT-planning enables the
delineation of a GTV for targeted dose escalation on
RT-planning CT scans. However, recurrent PC is usually
missed on RT-planning CT due to tumor densities equalto the surrounding tissues. Therefore, local recurrent PC
is managed so far by delivering RT to the entire fossa
prostatica, knowing that local recurrences tend to be
located around the vesicourethral anastomosis, but usu-
ally without having precise information where the recur-
rence is located and furthermore without having the
possibility to fuse a precise image-based information
with the RT-planning CT [15].
DCE-MRI in combination with EC was recently vali-
dated for the detection of local recurrent prostate can-
cer. The reported sensitivities and specificities ranged
between 71 – 88%, and 94 – 100%, respectively [7,8,18].
Nevertheless, since endorectal coil placement does not
allow image fusion with RT-planning CT, we assessed
the sensitivity and specificity of DCE-MRI without EC
for the detection of local recurrent prostate cancer.
Figure 2 (a) Correlation between tumor volume and PSA
(Spearman correlation coefficient, 0.83; p<0.0001). (b) Correlation
between tumor size and PSA (Spearman correlation coefficient,
0.47; p=0.03).
Figure 3 Scatter plot of pre-RT PSA levels in patients classified
as true positive and false negative.
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with positive DCE-MRI findings averaged 0.74±0.64 ng/mL
(median, 0.51 ng/mL, range, 0.11-2.38) and 0.57±0.58
ng/ml (median, 0.34 ng/mL; range, 0.08-2.38 ng/mL) for
the entire group. Against the background of lower pre-RT
PSA levels compared to previous studies that investigated
the sensitivity of DCE-MRI with EC in the detection of
PC recurrence (PSA, averaged 0.8 - 1.26 ng/mL), the sensi-
tivity of 67% reported in this study appears to be compar-
able to the performance of DCE-MRI with EC (sensitivity,
71 – 88%) [7,8,18].
In the normal post-surgical anatomy of the male pelvis
following radical prostatectomy variable degrees of post-
surgical fibrosis may be present [19,20]. However, no en-
hancement of the prostatic bed in the arterial phase after
administration of i.v. gadolinium had been described by
Allen et al. [17] or had been found in the control group
of Sciarra et al. [8]. In addition to these results we de-
scribe a frequent contrast enhancement inferior of the
vesicourethral anastomosis, anterior to the proximal ur-
ethra in 27 of the 33 post-RP patients (82%) with dis-
tinctive morphologic characteristics as described above
(Figure 4a and b). This finding would be familiar to radiol-
ogists with thorough experience of prostate- and urogeni-
tal MRI-imaging representing physiological periurethralvascular elements in the region of the diaphragma urogen-
itale, which can be seen regularly in contrast enhanced
MRI of the male pelvis without prior surgery [17,21,22]. Six
of the 33 patients (18%) did not exhibit these characteristic
changes. This might be explained by varying resection mar-
gins during RP. To avoid false positive readings knowledge
of this non-disease-specific structure is crucial for correct
image interpretation. Local recurrent tumor nodules tend
to be located most frequently around the posterior and lat-
eral aspects of the vesico-urethral anastomosis and rather
rarely in the anterior aspects as we found in our cohort
which is in concordance with previous studies [15].
Limitations of the study
First, this is a retrospective study and the results need to
be confirmed in future prospective clinical trials.
Second, histopathologic confirmation of the DCE-MRI
findings was not available. However, detection rates using
ultrasound or MRI guided biopsy are reported to be low
(range, 30 – 66%), with a positive biopsy of less than 30%
in patients with PSA levels <1 ng/mL [5,8,23-25].
We used the post-RT DCE-MRI (which was performed
at median 15 months after salvage RT) and complete PSA
response as a negative control. This is justifiable, since the
combination of a negative post-RT DCE-MRI and unre-
markable PSA levels rule out macroscopic disease. Whether
the high true negative rate reported in this study stands up
Figure 4 Contrast enhancement at the anterior aspect of the proximal urethra immediately below the vesicourethral anastomosis on
pre-RT DCE-MRI which was not associated to the patient’s recurrent prostate cancer (a) (arrowhead). Post-RT DCE-MRI demonstrating no
obvious change of this structure following RT (b).
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rent PC needs further investigation, however, our high true
negative rate confirms reports of other authors [8,17].Conclusions
DCE-MRI without endorectal coil may detect local re-
current PC at low PSA levels with acceptable accuracy.
All false negative DCE-MRI scans were detected using a
PSA cut-off of ≥0.54 ng/mL. This image modality may
therefore be considered in radiation oncology as a tool
to more accurately define the gross tumor volume to in-
crease the efficacy of salvage radiation treatment and to
decrease radiation side effects.Competing interests
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